Procedimientos, técnicas y comunicaciones en Urología, Geriatría, Anestesia y Endocrinología.
Contenido principal del artículo
Resumen
En 1995, se diagnosticaron cerca de 244,000 casos nuevos de cáncer de la próstata en los Estados Unidos. La mortalidad por esta causa llegó a cerca de 40,000 pacientes. El riesgo de padecer cáncer de próstata es en la población general de 8%.' La incidencia de sospecha de cáncer de próstata mediante tacto rectal y APE es de 10-15% en hombres de 50 años, el cual aumenta hasta 40% a la edad de 80 años.
Detalles del artículo
Cómo citar
Referencias
Bazinet M. Vallue of sytematic transítion zone biopsies in the early detection of prestare cancer. J Urol 1996;155:605-6.
Dalkin, Ahmann, Kopp. Prostate specífic antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. The Journal of Urology 1993;150: 1837-1839.
Rosen MA. lmpact of prostate-specific antigen screening on the natural history of prestare cáncer. Urology 1995;46:757-68.
Riehman, Rhodes, Cook, Grose, Bruskewitz. Annlysis of variation in prostate specific antigen values. Urology 1993;42(4):807-812.
Gilligand FO y Key CD. Male genital cancer. Cancer 1995;75: 295-315.
Smith DS y Catalana WJ. The nature of prostate cancer detected through prostate specific antigen based screening, J Urol 1994; 152:1732-36.
Wang WC, Valenzuela LA. Murphy GP. Purification of a human prostate specifíc antigen. Invest Urol 1979;17:158-63.
Partin AW, Osterling JE. The clinical usefulness of prostate specific antigen update 1994. A. W. the Joumal of Urology 1994;152: 1358-1368.
Kutiyama M, Wang MC, Papsidero LD. Killian Cs, Shimano T, Valenzuela L, Nishiura. T, Murphy GP y Chu TM. Quanntatíon of prestarespecíñc antigen in serum by sensitive enzyme immunoassay. Cáncer Res l 980;40:4658.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, y Redwin E. Prostatic-speciflc antigen nnd prostatic AA, A serum marker for adenocarcinoma of the prestare. New Engl J Med 1987;317:909.
Osterling JE. Prostate specific antigen: A crítícal assessment of the most useful tumor marker for adenocarcinoma of the prestare. J Urol 1991;145:907-923.
Charles B. Brendler MD. Prostate specific antíge: Its role in the diagnosis and stagging of prostate cancer. Controversies in the management of pros tate. Cancer l990;Part 4:4- I 1.
Christensson A, Bjork T. Nilsson O, Dahlen U, Matikaien T, Cockett ATK, Abrahamsson P y Lilja H. Serum prostate specific antígen complexed to alfa 1-antichymotrypsin as an indicator of prestare cancer. J Urol 1993;150: 100-105.
Osterling MD, Lilja MD. Prostate specific antigen: The value of molecular forms and age specific reference ranges. The Michígan Prostate Center and the University of Michigan Ann Arbor Michigan, and Department of Clinical Chemistry Lund University Malmo. Sweeden, 1994.
Stamey TA. Second stanford conference on intenational standarization of prostate-specific antigen ímmunoassays: September 1 and 2, 1994. Urology 1995;45: 173-83.
Osterling JE, Lilja H. Wag TJ et al. Molecular forms of prostate specific antigen and the human kallikrein gene family: A new era. Urology 1995;45:729-44.
Partin AW, Osterling JE. The clinical usefulness of prostate specific antigen update 1994. J Urol 1994;152:1358-1368.
Haab F, Meulemans A, Boccon-Gibod L, Dauge MC, Delmas V·,Hennequin C, y Benbunan D. Efect of radition therapy after radical prestatectomy on serurn prostate-specific antigen measured by an ultrasensitive assay, Urology 1995;45:1022-27.
Brawer M. Laboratory studies for the detection of carcinoma of the prostate. The Urol Clin North Am 1990:7:759-68.
Osterling JE, Jacobsen SJ, Chute CG, Guess HA, Dírman Cj, Panser LA, Lieber MM. Serum prostate-specific antigen in community-based population of healthy men: establishment of age-specific reference ranges, JAMA 1993;270:860-64.
Resgl A. Pointer J, Hominger W, Ennemosr O, Strasser H. Kolcker H y Bartsch G. Comparation of different prostate-specific antigen cutpoints for early detection of prostate cancer. Results of a large screening study. Urology 1995;45:662-65.
Bangma CH, Kranse P. Blijmberg BG, Schroder FH. The valúe of screening test in the detection of prostate cáncer. Part II: Retrospective analysis of free total prostate-specific analysís ratio, age-specific reference ranges, and PSA density. Urology l995;46:779-84.